Published on 8 Nov 2021 on Insider Monkey via Yahoo Finance

Here’s Why You Should Consider Investing in Acceleron Pharma (XLRN)

Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. A return of 1.18% was delivered by the fund’s institutional shares for the third quarter of 2021, outperforming both its S&P 500 and Russell 3000 Health Care benchmarks that delivered 0.58% and 0.17% returns respectively for the same period. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Baron Funds, in its Q3 2021 investor letter, mentioned Acceleron Pharma Inc. (NASDAQ: XLRN) and discussed its stance on the firm. Acceleron Pharma Inc. is a Massachusetts, United States-based biopharmaceutical company with a $10.5 billion market capitalization. XLRN delivered a 35.52% return since the beginning of the year, while its 12-month returns are up by 52.84%. The stock closed at $173.38 per share on November 5, 2021.

Here is what Baron Funds has to say about Acceleron Pharma Inc. in its Q3 2021 investor letter: